SCHEMBL2451785

SCHEMBL2451785

Clc1ccccc1C(=NN1CCCCCC1)n1ccnc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
LMNA P02545 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NR1I2 O75469 1/20 0.35
NR3C1 P04150 1/20 0.35
HTR1A P08908 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CNR1 P21554 1/20 0.35
TBXA2R P21731 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2456250 1.00 MAPT (0.40) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2456251 1.00 MAPT (0.40) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2454555 0.99 MAPT (0.38) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2454553 0.99 MAPT (0.38) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2451390 0.88 MGLL (0.44) MAPTLMNATDP1RAB9ASMN1; SMN2
SCHEMBL2451392 0.88 MGLL (0.44) MAPTLMNATDP1RAB9ASMN1; SMN2
SCHEMBL2449583 0.86 MAPT (0.40) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2449581 0.86 MAPT (0.40) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2449411 0.86 MAPT (0.40) MAPTALDH1A1ADRB2ADRB1ADRB3
SCHEMBL2452678 0.85 MAPT (0.46) MAPTADRB2ADRB1ADRB3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 MAPT 4346/4885ALDH1A1 831/4885ADRB2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.